相关临床试验
23
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
8
34.8%
已完成
6
26.1%
Enrolling By Invitation
2
8.7%
招募中
1
4.3%
暂停
1
4.3%
Temporarily Not Available
1
4.3%
终止
1
4.3%
撤回
3
13.0%
暂无批准数据
- REGENXBIO Inc. appointed Greg Ciongoli, Founder and Managing Partner of Adiumentum Capital Management, to its Board of Directors effective August 25, 2026. - Mr. Ciongoli brings over 16 years of biotechnology investing and capital allocation experience from The Baupost Group to support REGENXBIO's transition into a global commercial organization. - Concurrent with the appointment, independent directors Jerry Karabelas, Ph.D., and Jean Bennett, M.D., Ph.D., retired from the Board after years of distinguished service. - The appointment strengthens the Board as REGENXBIO advances a late-stage pipeline of potential first- and best-in-class AAV gene therapies.
- At ASRS 2026 in Montreal, durable treatment strategies for wet AMD dominated research, with gene therapy, intravitreal implant and optogenetic data presented across four days. - Ocular Therapeutix reported phase 3 SOL-1 results showing a single AXPAXLI injection maintained BCVA in 74.1% of patients at Week 36 versus 55.8% with monthly aflibercept. - Nanoscope Therapeutics presented 3-year REMAIN data showing durable BCVA gains of about 3 ETDRS lines with MCO-010 in retinitis pigmentosa, alongside a rolling BLA submission. - Belite Bio's phase 3 DRAGON trial of oral tinlarebant met its primary endpoint with a 36% reduction in retinal lesion growth versus placebo in Stargardt disease.
- A Complete Response Letter (CRL) is the FDA's formal notice that a drug application cannot be approved in its current form, citing deficiencies in safety, efficacy, manufacturing, or labeling. - CRLs can trigger severe market reactions, with single-day stock declines ranging from 2% (AbbVie) to 75% (Aldeyra Therapeutics), depending on the nature and severity of the deficiencies. - Companies can pursue Class 1 resubmissions for minor fixes (approximately two-month review) or Class 2 resubmissions for substantial changes (approximately six-month review), with successful resubmissions enabling significant stock recoveries. - Fortress Biotech's CUTX-101 and Capricor Therapeutics' deramiocel demonstrate that CRLs are not terminal, as both programs advanced toward approval following resubmission.
- The FDA approved Roche's Susvimo (ranibizumab injection) 100 mg/mL in May 2025 as the first continuous-delivery therapy for diabetic retinopathy, requiring only one refill every nine months. - The approval was supported by positive data from the Phase III Pavilion trial and applies to patients who have previously responded to at least two anti-VEGF injections. - Diabetic retinopathy affects nearly 10 million people in the US and over 100 million worldwide, with prevalence rising with age and affecting 15–30% of the diabetic population. - The diabetic retinopathy market is projected to grow significantly through 2036, driven by rising diabetes prevalence, novel pipeline candidates, and sustained-release treatment innovations.
- REGENXBIO announced the first patient has been dosed in the Phase IIb/III NAAVIGATE trial evaluating surabgene lomparvovec (sura-vec) for diabetic retinopathy using suprachoroidal delivery, triggering a $100 million milestone payment from AbbVie. - The multicenter, randomized, sham-controlled study will assess sura-vec at 1.0×10¹² GC/eye in patients with non-proliferative DR without center-involved diabetic macular edema, with a primary endpoint of ≥2-step DRSS improvement at one year. - Two-year data from the Phase II ALTITUDE trial showed durable efficacy with no intraocular inflammation (n=15), and longer-term follow-up data will be presented at the ASRS 2026 annual meeting. - Diabetic retinopathy affects nearly 10 million people in the United States and is the leading cause of vision loss among working-age adults globally, with current treatments often requiring repeated interventions.
- A new catalyst monitor report identifies 13 significant regulatory and clinical trial events expected in Q1 2026, based on key opinion leader interviews and predictive intelligence. - Major regulatory approval decisions are anticipated for GSK's depemokimab in asthma and sinusitis, Regenxbio's gene therapy for Hunter syndrome, and Omeros' narsoplimab for thrombotic microangiopathy. - Ongoing late-stage clinical trials from Xenon Pharmaceuticals, Cerevel, and Neumora are expected to deliver critical data across neurological and psychiatric conditions. - The pipeline momentum spans diverse therapeutic areas including respiratory diseases, rare genetic disorders, neurological conditions, and major depressive disorder.
- Tyrosine kinase inhibitors EYP-1901 and OTX-TKI have demonstrated preliminary results similar to aflibercept 2 mg in treating wet age-related macular degeneration. - Multiple gene therapy programs including ABBV-RGX-314, 4D-150, and ADVM-022 are currently under investigation for neovascular AMD treatment. - Vorolanib is designed for 6-month dosing intervals, potentially reducing treatment burden for wet AMD patients. - Experts anticipate numerous clinical readouts in the next year or two that could expand treatment options for neovascular AMD patients.
- REGENXBIO has initiated a pivotal Phase IIb/III clinical trial for diabetic retinopathy, marking a significant advancement in gene therapy for this vision-threatening complication. - The company's shares rose 1.27% after-hours following the announcement of the trial initiation, reflecting investor confidence in the therapeutic approach. - REGENXBIO continues to advance its pipeline with Duchenne muscular dystrophy trials on track and MPS II gene therapy progressing toward BLA submission. - Multiple investment firms maintain positive ratings on REGENXBIO stock, with Barclays maintaining an Overweight rating despite some price target adjustments across analysts.
- REGENXBIO will initiate a pivotal Phase IIb/III clinical trial for surabgene lomparvovec in diabetic retinopathy using suprachoroidal delivery, following positive two-year safety and efficacy data from the Phase II ALTITUDE trial. - The gene therapy demonstrated durable safety with no drug-related serious adverse events and no intraocular inflammation through two years at the highest dose level with prophylactic steroids. - AbbVie will pay REGENXBIO $100 million upon first subject dosed in the Phase IIb/III trial and an additional $100 million upon first subject dosed in a second Phase III trial under an amended collaboration agreement. - Diabetic retinopathy affects nearly 10 million people in the United States and is the leading cause of vision loss in adults between 24 and 75 years of age worldwide.
- Two major European gene therapy summits are addressing critical analytical and quality control challenges following recent regulatory setbacks, including Rocket Pharma's KRESLADI rejection that exposed CMC vulnerabilities. - The 6th Gene Therapy Analytical Development Summit Europe will bring together 24+ expert speakers and over 90 industry stakeholders to tackle analytics across the gene therapy lifecycle from Pre-IND/IMPD to BLA. - The inaugural Gene Therapy Potency Summit focuses specifically on potency assay challenges during the critical "sweet spot" of drug development from pre-clinical through commercialization. - Both events feature leading companies including Sarepta Therapeutics, Biogen, Sanofi, and regulatory experts from MHRA to provide practical solutions for assay validation and regulatory compliance.
